July 3, 2018
Neovacs announced the results of its Phase IIb clinical trial of the investigational agent IFNalpha Kinoid in patients with moderate to severe lupus (SLE).
The results show that IFNalpha Kinoid very significantly reduced the levels of type I interferon genes in the blood and tissue cells of people with lupus. High levels of these genes indicate active disease. Results also showed that the drug did not statistically improve symptoms according to one common tool used to measure disease activity — the BILAG-Based Composite Lupus Assessment (BICLA). However, it showed significant effectiveness according to another measurement tool (Lupus Low Disease Activity Score (LLDAS) and reduced steroid use.
“We are very pleased with these results that will enable us to move into phase III within a partnering to be finalised, in line with the objectives announced previously,” said Miguel Sieler Chief Executive Officer of Neovacs.
